NRx Pharmaceuticals develops ketamine-based and other drugs for central nervous system disorders such as depression and PTSD. It last closed at $2.45 on Nov 17, up 13.95% on the day. NRXP last reported earnings on Fri, Nov 13, 2026. The average 12-month price target from 2 analysts is $31.50 (+1185.7% from the last close), with a high of $51.00 and a low of $12.00.
Only 2 firms rated NRXP in the past 90 days, not enough for a consensus
Average 12-month target
$31.50
▲ 1185.7% upside
Based on 2 analysts who set a price target on NRXP in the past 90 days. The average target is $31.50, with a high of $51.00 and a low of $12.00, compared with the last close of $2.45.
Low $12.00Avg $31.50High $51.00
Blue marker: last close $2.45
Highest target$51.00
Average target$31.50
Lowest target$12.00
Latest rating changes
BTIGTarget raised
Nov 12Buy$10 → $12
Ascendiant CapitalTarget raised
Nov 2Buy$50 → $51
Ascendiant CapitalMaintained
Oct 1Buy$50
BTIGReiterated
Aug 18Buy$10
BTIGMaintained
Aug 7Buy$10
Date
Firm
Action
Rating
Price target
Nov 12
BTIG
Target raised
Buy
$10 → $12
Nov 2
Ascendiant Capital
Target raised
Buy
$50 → $51
Oct 1
Ascendiant Capital
Maintained
Buy
$50
Aug 18
BTIG
Reiterated
Buy
$10
Aug 7
BTIG
Maintained
Buy
$10
Loading…
Technical Analysis
NRXP · as of the Nov 17 close · updated after every close
Downtrend
The stock sits between its 20 and 50 day averages. It is 21% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 48). The nearest support is the 20 day average at $2.41, and the nearest resistance the swing high (Nov 11) at $2.50.
Short trendBearish
Long trendBearish
MomentumImproving
StretchNormal
VolatilityHigh, 8.2%/day
Key levels
$5.0652 week high+106.5%
$3.23100 day average+31.8%
$2.98200 day average+21.6%
$2.7750 day average+13.1%
$2.57Pivot R1+4.9%
$2.50Swing high (Nov 11)+2.0%
$2.45Last close
$2.4120 day average−1.6%
$2.34Pivot−4.5%
$2.24Swing low (Oct 23)−8.6%
$2.22Pivot S1−9.4%
$1.6252 week low−33.9%
Indicators
RSI (14)
48.32
Middle of its range
Neutral
MACD
-0.14
Above its signal line
Bullish
Stochastic
24.6
Middle of its range
Neutral
ADX (14)
32.6
Trending down
Williams %R
-49.5
Oversold below −80, overbought above −20
Neutral
CCI (20)
-38.3
Oversold below −100, overbought above 100
Neutral
Rate of change
+9.4%
Change over 10 sessions
Bullish
ATR (14)
$0.20
Typical daily range, 8.2% of price
MA 10Above
MA 20Above
MA 50Below
MA 100Below
MA 200Below
Downtrend
Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityNormal, 20.4%/day
Key levels
$5.0652 week high+106.5%
$3.23100 day average+31.8%
$2.98200 day average+21.6%
$2.7750 day average+13.1%
$2.57Pivot R1+4.9%
$2.50Swing high (Nov 11)+2.0%
$2.45Last close
$2.4120 day average−1.6%
$2.34Pivot−4.5%
$2.24Swing low (Oct 23)−8.6%
$2.22Pivot S1−9.4%
$1.6252 week low−33.9%
Indicators
RSI (14)
40.84
Middle of its range
Neutral
MACD
-0.23
Below its signal line
Bearish
Stochastic
14.2
Near the bottom of its range
Oversold
ADX (14)
24.9
Weak trend
Williams %R
-75.7
Oversold below −80, overbought above −20
Neutral
CCI (20)
-111.7
Oversold below −100, overbought above 100
Oversold
Rate of change
−27.9%
Change over 10 sessions
Bearish
ATR (14)
$0.50
Typical daily range, 20.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for NRXP
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how NRXP did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow NRXP usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How NRXP has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NRXP is in one of them and how their past NRXP trades turned out.
NRx Pharmaceuticals is a drug developer based in Wilmington, Delaware, focused on treatments for central nervous system disorders such as depression, post traumatic stress disorder, chronic pain and schizophrenia. Its lead product candidates are ketamine formulations, including a generic version called KETAFREE, and NRX-101, a combination of D-cycloserine and lurasidone, all still awaiting approval from the U.S. Food and Drug Administration. Through its majority owned subsidiary HOPE Therapeutics, the company also runs clinics in Florida that offer interventional psychiatry care to patients with treatment resistant depression and PTSD.